Vaccine Contract Manufacturing Market Size, Share, and Trends 2024 to 2034

Vaccine Contract Manufacturing Market Size and Forecast 2024 to 2034

The global vaccine contract manufacturing market size is estimated at USD 4.24 billion in 2024 and is anticipated to reach around USD 12.26 billion by 2034, growing at a CAGR of 11.20% between 2024 and 2034.

Vaccine Contract Manufacturing Market Key Takeaways

• North America led the market with the highest market share of 42% in 2023.
• Asia-Pacific is expected to grow at the fastest CAGR during the forecast period.
• By Vaccine Type, the attenuated vaccines segment has held the largest revenue share of 28% in 2023.
• By Vaccine Type, the inactivated inoculations segment is projected to expand at a remarkable CAGR of 12.7% during the projected period.
• By Workflow, the downstream segment generated more than 68% of revenue share in 2023.
• By Workflow, the upstream segment is anticipated to grow at the fastest CAGR over the projected period.
• By Application, the human-use segment held the major revenue share of 69% in 2023.
• By Application, the veterinary segment is estimated to grow at a noteworthy CAGR of 13.3% over the predicted period.

U.S. Vaccine Contract Manufacturing Market Size and Growth 2024 to 2034

The U.S. vaccine contract manufacturing market size accounted for USD 1.78 billion in 2024 and is estimated to be worth around USD 5.15 billion by 2034, growing at a CAGR of 11.30% from 2024 to 2034.

North America has held the largest revenue share 42% in 2023. North America commands a substantial share in the vaccine contract manufacturing market due to several factors. It benefits from a mature pharmaceutical and biotechnology industry, with a high demand for vaccines driven by a large population and a strong focus on healthcare. Additionally, the region boasts advanced manufacturing infrastructure, well-established regulatory frameworks, and a skilled workforce, making it an attractive hub for contract manufacturing organizations (CMOs).

The presence of major vaccine developers and government initiatives to promote vaccine manufacturing further solidify North America's dominant position in the market, positioning it as a key contributor to the industry's growth.

Asia-Pacific is estimated to observe the fastest expansion. The Asia-Pacific region commands significant growth in the vaccine contract manufacturing market due to several key factors. Firstly, it boasts a large and growing population, leading to increased demand for vaccines. Secondly, Asia-Pacific has a robust pharmaceutical and biotechnology industry, attracting global vaccine developers who seek cost-effective manufacturing solutions. Additionally, the region benefits from a skilled workforce and advanced manufacturing capabilities. Furthermore, favorable regulatory environments and lower labor costs make it an attractive destination for vaccine contract manufacturing. As a result, Asia-Pacific continues to be a major contributor to the global vaccine contract manufacturing market growth.

Market Overview

The vaccine contract manufacturing sector pertains to the domain where pharmaceutical firms enlist the services of external contract manufacturing entities for the production of vaccines. These contract manufacturing organizations (CMOs) possess the requisite infrastructure, specialized know-how, and dedicated facilities to manufacture vaccines on behalf of the original developers. This marketplace has witnessed substantial expansion recently, driven by rising vaccine demand, notably during global health emergencies such as the COVID-19 pandemic. It provides vaccine manufacturers with adaptability, scalability, and cost-effectiveness, allowing them to efficiently fulfill production requirements while upholding stringent quality standards and regulatory adherence.

Vaccine Contract Manufacturing Market Growth Factors

The vaccine contract manufacturing market has evolved as a critical component of the pharmaceutical industry. It involves pharmaceutical companies outsourcing the production of vaccines to specialized contract manufacturing organizations (CMOs). This outsourcing model allows vaccine manufacturers to leverage the expertise and infrastructure of CMOs, enabling efficient vaccine production while maintaining stringent quality and regulatory standards.

The vaccine contract manufacturing market has experienced remarkable growth due to several key trends and growth drivers. First and foremost, the COVID-19 pandemic underscored the importance of rapid vaccine development and manufacturing, driving increased demand for contract manufacturing services. Additionally, advancements in vaccine technology, such as mRNA-based vaccines, have opened new avenues for contract manufacturing. Furthermore, governments and global health organizations are increasingly investing in vaccine manufacturing infrastructure, fostering industry growth.

Despite its growth, the vaccine contract manufacturing industry faces significant challenges. One major obstacle is the complex regulatory landscape, which varies across regions and requires meticulous adherence to quality and safety standards. Supply chain disruptions, as seen during the pandemic, also pose challenges. Additionally, ensuring equitable access to vaccines worldwide remains a persistent challenge, as does addressing the potential for intellectual property disputes in vaccine manufacturing partnerships.

The vaccine contract manufacturing market presents lucrative business opportunities. Contract manufacturers can capitalize on the growing demand for vaccines by offering flexible and scalable production solutions. Moreover, investing in cutting-edge vaccine manufacturing technologies and infrastructure can position CMOs as industry leaders. Collaborations with vaccine developers, especially for emerging diseases, offer substantial growth potential. Diversification into vaccine formulation and packaging services can further enhance CMOs' value proposition.

In summary, the vaccine contract manufacturing market is witnessing robust growth driven by the urgency for vaccine production, technological advancements, and increased funding. However, it also faces challenges related to regulatory compliance, supply chain resilience, and equitable access. Businesses in this sector can thrive by focusing on innovation, strategic partnerships, and diversification, as the world continues to emphasize the critical role of vaccines in public health.

Market Scope

Market Dynamics

Driver

Increasing global vaccine demand

Increasing global vaccine demand is a pivotal driver propelling the growth of the vaccine contract manufacturing market. This surge in demand is primarily attributed to several factors, including the urgent need to respond to global health crises like the COVID-19 pandemic and the ongoing efforts to combat infectious diseases on a broader scale. Firstly, the COVID-19 pandemic underscored the critical importance of vaccine availability and accessibility on a global scale.

The need for rapid vaccine development and production reached unprecedented levels, leading vaccine developers to seek the support of contract manufacturing organizations (CMOs) to meet the surging requirements swiftly and efficiently. Furthermore, beyond pandemics, routine vaccination programs and an increased emphasis on preventative healthcare have fueled the consistent growth in vaccine demand.

As a result, pharmaceutical companies are turning to CMOs to enhance their production capabilities and ensure a reliable supply of vaccines to meet the healthcare needs of populations worldwide. In essence, increasing global vaccine demand acts as a potent catalyst for the expansion of the vaccine contract manufacturing market, highlighting its crucial role in addressing pressing public health challenges and sustaining a robust vaccine supply chain.

Restraints

Quality assurance and supply chain risk

Quality assurance and supply chain risk act as substantial impediments to the expansion of the vaccine contract manufacturing market. Upholding consistent vaccine quality stands as a paramount concern, given vaccines' critical role in safeguarding public health. Any deviations from established quality standards could result in product recalls, regulatory repercussions, and damage to the reputation of contract manufacturing organizations (CMOs).

The quest for the highest levels of safety and effectiveness demands rigorous oversight and continual investments in quality assurance protocols, which can prove resource-intensive and time-demanding. Furthermore, the vaccine supply chain remains susceptible to an array of vulnerabilities, encompassing shortages of essential raw materials, interruptions in transportation networks, and unforeseen global occurrences like pandemics or geopolitical tensions. These hazards can induce delays in vaccine production and distribution, consequently affecting CMOs' capacity to meet the escalating demand.

As the world's dependence on contract manufacturing for vaccines intensifies, the imperative of mitigating these risks takes on paramount significance for market expansion. CMOs must allocate resources to develop resilient supply chain management strategies, ensuring the dependable and punctual delivery of vaccines.

Opportunities

Diversification of services

Diversification of services within the vaccine contract manufacturing market is unlocking significant opportunities for growth and expansion. Beyond traditional vaccine production, contract manufacturing organizations (CMOs) are broadening their offerings to include vaccine formulation, fill-and-finish processes, packaging, and distribution services. This diversification enhances CMOs' appeal to vaccine developers by providing a one-stop solution for their manufacturing needs. It streamlines the supply chain and reduces the complexity of managing multiple partners, resulting in cost savings and improved efficiency.

Additionally, it offers comprehensive services that allow CMOs to cater to a broader range of vaccine types, including those with specific storage and administration requirements, such as gene-based vaccines like mRNA and viral vectors. This adaptability positions CMOs as versatile partners capable of addressing diverse vaccine development projects.

Moreover, as global vaccine distribution efforts expand, having the capacity to handle various aspects of vaccine manufacturing and logistics positions CMOs to play a pivotal role in ensuring equitable vaccine access worldwide. Consequently, diversification of services is a strategic move that not only strengthens CMOs' market presence but also contributes to addressing global health challenges.

Impact of COVID-19

The COVID-19 pandemic had a profound impact on the vaccine contract manufacturing market. The urgent need for vaccine production led to increased demand for contract manufacturing services, especially for mRNA and viral vector-based vaccines. CMOs played a crucial role in scaling up vaccine manufacturing, contributing to the rapid development and distribution of COVID-19 vaccines. This experience heightened awareness of the strategic importance of CMOs in pandemic response and has led to continued growth opportunities in the vaccine contract manufacturing sector. It also accelerated investments in advanced manufacturing technologies, reinforcing the industry's ability to respond to future health crises.

Vaccine Type Insights

According to the vaccine type, the attenuated vaccines sector has held a 28% revenue share in 2023. The attenuated vaccines segment holds a significant share in the vaccine contract manufacturing market due to several factors. Attenuated vaccines, which contain weakened forms of pathogens, require specialized expertise and facilities for safe and effective production. Contract manufacturing organizations (CMOs) with experience in handling live, attenuated strains are in high demand.

Additionally, attenuated vaccines often have a long history of efficacy, making them essential for preventing various diseases. The established market for these vaccines drives consistent demand for manufacturing services, contributing to the segment's substantial share in the contract manufacturing market.

The inactivated inoculations segment is anticipated to expand at a significant CAGR of 12.7% during the projected period. The dominance growth of the inactivated inoculations segment in the vaccine contract manufacturing market is attributed to its long-standing reputation for safety and effectiveness. Inactivated vaccines have a well-established history of use, making them a preferred option for vaccine developers. Contract manufacturing organizations (CMOs) possess extensive know-how and proficiency in producing inactivated vaccines, instilling trust in their capacity to comply with stringent regulatory requirements.

Furthermore, inactivated vaccines play a vital role in combatting various infectious diseases, such as influenza and polio, ensuring a consistent demand for manufacturing services and reinforcing the segment's commanding position within the market.

Workflow Insights

In 2023, the downstream segment had the highest market share of 68% on the basis of the Application. The downstream segment holds a major share in the vaccine contract manufacturing market because it encompasses critical processes like formulation, fill-and-finish, packaging, and distribution. These stages are essential for ensuring vaccine safety, efficacy, and accessibility. Vaccine developers often rely on contract manufacturing organizations (CMOs) to handle these complex downstream tasks, as they require specialized equipment, expertise, and regulatory compliance. By outsourcing these crucial steps to CMOs, vaccine developers can streamline their operations, reduce costs, and expedite vaccine production, making the downstream segment a pivotal and dominant component of the vaccine contract manufacturing market.

The upstream is anticipated to expand at the fastest rate over the projected period. The Upstream segment holds a major share in the vaccine contract manufacturing market primarily because it encompasses the crucial early stages of vaccine production. Upstream processes involve cell culture, fermentation, and initial vaccine development, which are complex and resource-intensive phases. These processes are essential for generating the primary vaccine substance or antigen.

As the foundation of vaccine manufacturing, any efficiency improvements or technological advancements in the upstream segment have a significant impact on overall production capacity and quality. Hence, it plays a pivotal role in the vaccine manufacturing process and holds a major share in the market.

Application Insights

The human-use segment held the largest revenue share of 69% in 2023. The human-use segment holds a major share in the vaccine contract manufacturing market due to the significant and consistent demand for human vaccines. Vaccination is a cornerstone of public health programs globally, addressing various infectious diseases and preventing their spread. Consequently, pharmaceutical companies and governments regularly require contract manufacturing services to meet the production needs of human vaccines. This consistent demand, along with the need for specialized expertise in human vaccine manufacturing, drives the dominance of the human-use segment within the vaccine contract manufacturing market.

The veterinary sector is anticipated to grow at a significantly faster rate, registering a CAGR of 13.3% over the predicted period. The veterinary segment commands a substantial portion of the vaccine contract manufacturing market share due to the escalating focus on animal well-being and the increasing requirement for vaccines to safeguard livestock and companion animals from diseases. This sector gains traction from the growing recognition of diseases that can transmit between animals and humans, highlighting the importance of vaccination in both spheres. Furthermore, the regulatory pathways for veterinary vaccines often involve quicker and less intricate approval processes than those for human vaccines, making them an appealing avenue for contract manufacturing firms. Consequently, the veterinary vaccine domain continues its robust expansion, contributing significantly to the overall market landscape.

Vaccine Contract Manufacturing Market Companies

• Lonza
• FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• Ajinomoto Althea, Inc.
• Merck KgaA
• Cytovance Biologics
• Catalent, Inc.
• IDT Biologika GmbH
• Albany Molecular Research, Inc.
• PRA Health Sciences
• ICON plc.
• Pharmaceutical Product Development, LLC
• Cobra Bio
• Paragon Bioservices, Inc.

Recent Developments

• In July 2023, Merck unveiled plans to expand its laboratory space and production capabilities in Lenexa, Kansas, USA. This expansion aimed to enhance its capacity for manufacturing cell culture media and accelerate the production of innovative dry powder media, crucial for processes like vaccine manufacturing and gene therapy.
• FUJIFILM Corporation, in June 2023, announced the establishment of a commercial office in Tokyo. This office was strategically positioned to offer improved sales and customer support services, particularly catering to Asia-based pharmaceutical and biotechnology firms, for their contract development and manufacturing needs in biologics and advanced therapies.
• Lonza made a significant move in June 2023 by acquiring Synaffix B.V. This acquisition was focused on bolstering Lonza's bioconjugate capabilities through integration with Synaffix's technology, further strengthening their Center of Excellence dedicated to bioconjugate technology development.
• Lonza and Vertex Pharmaceuticals Incorporated, also in June 2023, entered into a strategic partnership to scale up manufacturing and support the commercial production of Vertex's T1D cell therapy portfolio. They additionally planned to jointly invest in the construction of a dedicated facility in Portsmouth, New Hampshire, USA.
• In April 2023, FUJIFILM Diosynth Biotechnologies announced its acquisition of 41 acres of adjacent land to its existing RTP campus in North Carolina. This expansion aimed to accelerate their production capabilities for biologics manufacturing and development.
• Cytovance Biologics, Inc. partnered with Phenotypeca Limited in March 2023 to provide optimized strains of Saccharomyces cerevisiae for biopharmaceutical manufacturing. This collaboration enhanced Cytovance Biologics' leadership in the production of microbial-derived active pharmaceutical ingredients (API) and expanded Phenotypeca's market presence.
• IDT Biologika joined forces with CanVirex, a biotechnology company, to manufacture oncolytic measles virus-based therapeutics for anti-cancer treatment under cGMP conditions. IDT utilized its advanced manufacturing infrastructure for this collaboration.
• In January 2023, Ajinomoto Co., Inc. entered into a partnership with Exelixis, Inc. to jointly discover and develop novel Antibody-Drug Conjugates (ADCs) for cancer treatment. The collaboration leveraged Ajinomoto's AJICAP technology to create advanced ADCs with improved efficacy and reduced toxicity.

Segments Covered in the Report

By Vaccine Type

• Attenuated
• Inactivated
• Subunit-based
• Toxoid-based
• DNA-based

By Workflow

• Downstream
• Upstream

By Application

• Human Use
• Veterinary

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa